The majority of patients with NSHPT are identified as having homozygous or compound heterozygous pathogenic variants of CASR and many patients have a family history of hypocalciuric hypercalcemia [1, 2]. This evidence concerns the gene CASR and familial hypocalciuric hypercalcemia.